The Technical AnalystExchange: TWO Sector: Healthcare Industry: Biotechnology
Medigen Vaccine Biologics Price, Forecast, Insider, Ratings, Fundamentals & Signals
-1.12% TWD53.00
America/New_York / 7 mai 2024 @ 01:30
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 17 416 mill |
| EPS: | -3.53 |
| P/E: | -15.01 |
| Earnings Date: | May 02, 2024 |
| SharesOutstanding: | 328.61 mill |
| Avg Daily Volume: | 1.307 mill |
| RATING 2024-05-06 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Sell | |
| Return On Asset: | Neutral | |
| DE: | Sell | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 | |
| Revenue | n/a | n/a | ||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | n/a | |||||
| Debt | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -15.01 | sector: PE 34.77 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.26x |
| Company: PE -15.01 | industry: PE 58.06 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
TWD 51.70 - 54.30 ( +/- 2.46%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | TWD53.00 (-1.12% ) |
| Volume | 1.030 mill |
| Avg. Vol. | 1.307 mill |
| % of Avg. Vol | 78.75 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For 6547.TWO
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
6547.TWO
Medigen Vaccine Biologics Corporation, a biotechnology drug company, focuses on the development and production of vaccines and biologics in Taiwan and internationally. The company is developing enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection; influenza vaccine, which has completed Phase III clinical trial to treat influenza; dengue vaccine, which has completed Phase II clinical trial for the treatment of dengue fever; respiratory cell fusion virus (RSV) antibody, which is in Phase I clinical trial for the prevention of RSV infection; and COVID-19 vaccine, which is in Phase III clinical trial to prevent COVID-19- severe special infectious pneumonia. Medigen Vaccine Biologics Corporation was founded in 2012 and is based in Taipei, Taiwan. Medigen Vaccine Biologics Corporation is a subsidiary of Medigen Biotechnology Corp.